共 170 条
[11]
Borley J(2000)Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy Clin Cancer Res 6 1415-895
[12]
Brown R(2008)Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients Ginekol Pol 79 826-509
[13]
Seeber LM(2019)A whole-genome CRISPR screen identifies a role of MSH2 in cisplatin-mediated cell death in muscle-invasive bladder cancer Eur Urol 75 242-589
[14]
Van Diest PJ(2002)Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: identification of three novel germ-line mutations in promoter of the hMSH2 gene Cancer Res 62 38-6447
[15]
Sameer A(2003)Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples J Clin Investig 111 887-10418
[16]
Nissar S(2010)Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer Aust N Z J Obstet Gynaecol 48 505-69
[17]
Fatima K(1996)The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin Chem Biol 3 579-2293
[18]
Martin LP(1996)Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d (GpG) adduct Proc Natl Acad Sci U S A 93 6443-1514
[19]
Hamilton TC(2011)hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis J Biol Chem 286 10411-177.e9
[20]
Schilder RJ(2018)Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells Eur J Pharm Sci 123 56-4534